Understand the source comparison
KPV vs Conventional RA Therapies: Mechanistic Comparison
KPV (investigational) NF-κB translocation inhibition 40–60% TNF-α, 50–70% IL-6 (in vitro) Unknown. Preclinical only Not established Research-grade compound with upstream anti-inflammatory action; no human safety or efficacy data Anti-TNF Biologics (adalimumab,
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- KPV (investigational)
- NF-κB translocation inhibition
- 40–60% TNF-α, 50–70% IL-6 (in vitro)
- Unknown. Preclinical only
- Not established
- Research-grade compound with upstream anti-inflammatory action; no human safety or efficacy data
- Anti-TNF Biologics (adalimumab, etanercept)
- TNF-α receptor blockade
- Neutralizes circulating TNF-α
- 2–3× baseline TB/fungal infection rate
- Quarterly TB screening, annual chest X-ray
- Gold standard for moderate-severe RA; proven efficacy but significant infection risk
- Methotrexate (DMARD)
- Dihydrofolate reductase inhibition → purine synthesis blockade
- Broad immunosuppression
- Moderate opportunistic infection risk
- Monthly CBC, liver enzymes, creatinine
- First-line DMARD; effective but requires liver and bone marrow monitoring
- JAK Inhibitors (tofacitinib)
- Janus kinase pathway blockade → reduced STAT signaling
- Blocks IL-6, IL-12, IL-23 signaling
- Black box warning for thromboembolic events
- Quarterly CBC, lipid panel
- Oral alternative to biologics; cardiovascular risk profile limits use
- Corticosteroids (prednisone)
- Glucocorticoid receptor activation → cytokine transcription suppression
- Broad but non-specific
- Dose-dependent immunosuppression
- Blood glucose, bone density, adrenal function
- Short-term bridge therapy only; long-term use causes metabolic/bone complications
- The bottom line: KPV's NF-κB inhibition sits upstream of every other RA therapy. Biologics intercept cytokines after they're produced. Methotrexate blocks cell proliferation broadly. KPV prevents inflammatory gene transcription without blocking normal immune responses. The theoretical advantage is inflammation control without systemic immunosuppression. The practical gap: no Phase I safety data, no established human dosing, no long-term toxicity profile. Preclinical promise does not equal clinical utility.